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Intravenous Ghrelin Administration Increases Alcohol
Craving in Alcohol-Dependent Heavy Drinkers:
A Preliminary Investigation
Lorenzo Leggio, William H. Zywiak, Samuel R. Fricchione, Steven M. Edwards,
Suzanne M. de la Monte, Robert M. Swift, and George A. Kenna
Background: There is a need to identify novel pharmacologic targets to treat alcoholism. Animal and human studies suggest a role for
ghrelin in the neurobiology of alcohol dependence and craving. Here, we were the first to test the hypothesis that intravenous
administration of exogenous ghrelin acutely increases alcohol craving.
Methods: This was a double-blind, placebo-controlled human laboratory proof-of-concept study. Nontreatment-seeking, alcohol-
dependent, heavy-drinking individuals were randomized to receive intravenous ghrelin 1 mcg/kg, 3 mcg/kg or 0 mcg/kg (placebo),
followed by a cue-reactivity procedure, during which participants were exposed to neutral (juice) and alcohol cues. The primary outcome
variable was the increase in alcohol craving (also called urge) for alcohol, assessed by the Alcohol Visual Analogue Scale.
Results: Out of 103 screenings, 45 individuals received the study drug. Repeated measures of analysis of covariance revealed a group
effect across ghrelin doses in increasing alcohol craving (p  .05). A dose-specific examination revealed a significant effect of ghrelin 3
mcg/kg versus placebo in increasing alcohol craving (p  .05) with a large effect size (d ¼ .94). By contrast, no significant ghrelin effect
was found in increasing either urge to drink juice or food craving (p ¼ ns). No significant differences in side effects were found (p ¼ ns).
Conclusions: Intravenous administration of exogenous ghrelin increased alcohol craving in alcohol-dependent heavy-drinking
individuals. Although the small sample requires confirmatory studies, these findings provide preliminary evidence that ghrelin may
play a role in the neurobiology of alcohol craving, thus demonstrating a novel pharmacologic target for treatment.
Key Words: Alcoholism, craving, cue-reactivity, feeding peptides,
ghrelin, neuroendocrinology
Alcoholism is one of the leading causes of mortality andmorbidity (1,2). Therefore, interventions for alcoholism mayhave important implications. Hence, there is a need to
identify new pathways that may serve as pharmacologic targets
for treatment (3).
Ghrelin is a 28-amino-acid peptide acting as the endogenous
ligand for the growth hormone secretagogue receptor (GHS-R1a)
(4). Ghrelin activates hypothalamic orexigenic neurons and
inhibits anorectic neurons to induce hunger and stimulate
feeding (5,6). Growth hormone secretagogue receptors are highly
co-expressed with dopamine receptors in the midbrain, raphe
nuclei, and ventral tegmental area (7–9), suggesting that ghrelin
modulates reward processing. In mice, ghrelin administration
intraperitoneally (10) or centrally into the ventral tegmental area
(11,12) activates measures associated with reward.
Preliminary human studies show differences in endogenous
blood ghrelin levels in actively drinking (13–15) and abstinent
alcoholics (16,17) and changes in ghrelin levels over time based
on the drinking status (18). Some studies indicate a significant
positive correlation between ghrelin levels and alcohol craving
[(13,18,19) but see (17)]. However, while animal studies tested the
direct effects of exogenous ghrelin administration, human studies
were limited to measuring endogenous blood ghrelin levels and
retrospective measures of alcohol craving, thus significantly
limiting their bench-to-bedside value (20). There is no human
evidence that manipulations of ghrelin signaling via administra-
tion of exogenous ghrelin increases alcohol-seeking behaviors,
such as alcohol craving. This was the first study testing this
hypothesis.
Methods and Materials
Subjects
Design and Setting. This was a three-group between-subject,
double-blind, placebo-controlled randomized human laboratory
proof-of-concept study, conducted at the Brown University Center
for Alcohol and Addiction Studies, Providence, Rhode Island. The
study was approved by the Brown University Institutional Review
Board. The use of synthetic human ghrelin was approved under
the Food and Drug Administration Investigational New Drug
109,242.
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Study Drug. Current Good Manufacturing Practice human
acetylated ghrelin was purchased from PolyPeptide Laboratories
(Torrance, California). The purity of the peptide was 95% and its
authenticity was confirmed by mass spectrometry, tandem mass
spectrometry analysis, and amino acid analysis. The final ghrelin
solution demonstrated excellent stability after 72 hours and was
sterile and free of detectable pyrogens. The final solution was
always prepared 48 hours before its administration.
Study Population. Nontreatment-seeking alcohol-dependent
men and women were screened according to inclusion/exclusion
criteria (Supplement 1).
Study Overview. Potential participants recruited via mass
media were prescreened by phone. Potentially eligible partici-
pants came to our facility. After complete description of the
study, written informed consent was obtained and then screening
took place (visit 1). Eligible participants were randomized to
ghrelin 1 mcg/kg, 3 mcg/kg, or 0 mcg/kg (placebo) and the
experimental session (visit 2) was scheduled. The experimental
session consisted of a 10-minute administration of ghrelin/
placebo, followed by a cue-reactivity procedure. A breath alcohol
concentration of .00 was required at each visit. Compensation in
the form of cash was provided at each visit.
Experimental Session. The session was conducted individually
in a one-way mirror room. Subjects came to our laboratory after
having fasted. An intravenous cannula was placed, and a fixed light
breakfast was served, i.e. 700 kJ, approximately 62% carbohy-
drate, 13% protein, and 25% fat (11,21–23). Consistent with
previous cue-reactivity studies (24,25), participants were exposed
to visual, tactile, olfactory, and proprioceptive stimuli associated
with neutral and alcohol beverages. As for the neutral condition, a
palatable nonalcoholic beverage, rather than water (24,25), was
included. Specifically, consistent with Rohsenow et al. (26), a juice
condition was used, i.e., a 295 mL bottle of a commercially
available fruit punch. Additionally, food craving was assessed via
the General Food Cravings Questionnaire-State (27).
Before intravenous ghrelin/placebo administration, participants
underwent a 3-minute relaxation period to collect baseline levels
of urge and physiological arousal (Table 1). Then, a staff member
entered the room with a tray, covered by an inverted pitcher,
containing the fruit punch bottle and a glass. The pitcher was
removed, the bottle was opened, and the glass was filled. The
staff member left the room, and an audiotape instructed the
participant to sniff the glass of juice when they heard high tones
and stop sniffing when they heard low tones. This procedure
included thirteen 5-second olfactory exposures during each
3-minute trial. Next, participants underwent a 3-minute alcohol
cue exposure that was identical to the previous procedure except
the juice bottle was replaced with the appropriate commercially
labeled alcohol bottle. After the stimuli were removed, a relaxa-
tion period took place, and a second juice trial and finally a
second alcohol trial were presented (Table 1). For urge, Alcohol
Visual Analogue Scale and Juice Visual Analogue Scale were rated
on 11-point anchored Likert-type scales (26). The Alcohol Atten-
tion Scale was used to assess attention to sight/smell of alcohol
cues (24). We also assessed attention to sight/smell of juice cues,
adapting the Alcohol Attention Scale (i.e., Juice Attention Scale).
Previous studies indicate that alcohol cue-elicited craving may
be associated with parallel increases in mean arterial pressure
(MAP), heart rate (HR), and salivation (28). In this study, we
measured HR and salivation as secondary outcomes, while we
monitored MAP only for safety reasons. In fact, a reduction of
blood pressure is a possible common transitory side effect of
intravenous ghrelin; therefore, blood pressure might have exhib-
ited low validity in our paradigm. Mean arterial pressure and HR
were obtained using using a monitoring machine. As for measuring
salivation, participants placed three dental rolls in their mouths;
rolls were weighed immediately before and after the cue-reactivity
with an analytical scale, so that the net difference indicated the
saliva mass produced during cue-reactivity (29). After all proce-
dures were completed, a meal was provided, a postsession
debriefing was performed, and then participants were released.
The Systematic Assessment for Treatment Emergent Events was
used for adverse events (30,31). Approximately a week after visit 2,
a brief safety follow-up (visit 3) took place, during which a brief
motivational session to reduce alcohol use was provided, based on
the motivational enhancement therapy manual (32).
Blood Samples Analysis. Blood samples were collected at six
time points (Table 1), centrifuged and stored at 801C. Samples
were analyzed together at the end of the study to maintain the
blind. Total serum ghrelin levels were determined using a fluores-
cent bead-based Bio-Plex assay (Bio-Rad, Hercules, California) follow-
ing the manufacturer’s protocol. Results were expressed as pg/mL.
Statistical Analysis
Preliminary analyses included the examination of the distribu-
tions of the outcome measures. All outcome measures
Table 1. Study Activities and Timeline During the Experimental Session
Time Point (Minutes) Procedures and/or Assessments
40 Breakfast (700 kJ)
15 Baseline: Blood Sample #1, Urge to Drink Alcohol, Urge to Drink Juice, Food Craving
13 Baseline: Mean Arterial Pressure, Heart Rate
10 Study Drug Intravenous (IV) Administration: Ghrelin 1 mcg/kg, Ghrelin 3 mcg/kg, or 0 mcg/kg (Placebo)
3 Juice Trial #1: Mean Arterial Pressure, Heart Rate, Saliva Mass
6 Post-Juice Trial #1: Urge to Drink Juice, Juice Attention Scale, Blood Sample #2, Relaxation Period
9 Alcohol Trial #1: Mean Arterial Pressure, Heart Rate, Saliva Mass
17 Post-Alcohol Trial #1: Urge to Drink Alcohol, Alcohol Attention Scale, Blood Sample #3, Adverse Events, Food
Craving, Relaxation Period
20 Juice Trial #2: Mean Arterial Pressure, Heart Rate, Saliva Mass
23 Post-Juice Trial #2: Urge to Drink Juice, Juice Attention Scale, Blood Sample #4, Relaxation Period
26 Alcohol Trial #2: Mean Arterial Pressure, Heart Rate, Saliva Mass
29 Post-Alcohol Trial #2: Urge to Drink Alcohol, Alcohol Attention Scale, Blood Sample #5, Adverse Events
46 Relaxation Period
48 Postexperiment Assessment: Blood Sample #6, Urge to Drink Alcohol, Food Craving
L. Leggio et al. BIOL PSYCHIATRY 2014;76:734–741 735
www.sobp.org/journal
approximated a normal distribution as indicated by skewness and
kurtosis within 2 to 2. The primary statistical method used was
repeated measures analysis of covariance (ANCOVA). The number
of standard drink units consumed the day before was chosen as a
covariate in the model, since recent prior alcohol consumption is
known to affect craving (33,34). Furthermore, consistent with
previous ghrelin-related literature [e.g., (35,36)], total ghrelin
serum level at baseline was also fitted as covariate. Typically,
the baseline assessment (when available) for the dependent
measure was also entered as a covariate, unless a change from
baseline score was used as the dependent measure. This was a
proof-of-concept study and the sample size was based on the
effects of ghrelin on urge to drink alcohol only. The interaction
with nonalcoholic cues (juice) was only an exploratory outcome,
given that the study was not powered for a dose  cue type
interaction. We also conducted a number of pairwise correlations
between total ghrelin serum levels and a number of other
variables of interest (alcohol craving, food craving, etc.). All
pairwise comparisons were conducted with a Bonferroni correc-
tion. SPSS version 21 (IBM SPSS Statistics for Windows, Armonk,
New York) was used.
Results
Sample Description
Forty-five alcohol-dependent heavy-drinking individuals
received the study drug. Figure S1 in Supplement 1 outlines
the trial flow chart. Demographics and baseline characteristics are
outlined in Table 2.
Urge to Drink Alcohol (Primary End Point)
Increase in alcohol urge after intravenous ghrelin administra-
tion versus placebo was the primary aim. Repeated measures
(two trials) ANCOVAs were conducted for the increase in alcohol
urge (i.e., increase in the Alcohol Visual Analogue Scale score)
during the cue-reactivity procedure relative to the predrug
urge level. Ghrelin dose was statistically related to urge increase
(F2,40 ¼ 3.36, p ¼ .045) (Figure 1A). Pairwise comparisons revealed
that alcohol urge was significantly greater for ghrelin 3 mcg/kg
than placebo (p ¼ .046). The effect size for the increase in urge
to drink alcohol for ghrelin 3 mcg/kg versus placebo was large
(d ¼ .94). No statistically significant differences were found in the
ghrelin 1 mcg/kg versus placebo conditions (p ¼ 1.00) or
between ghrelin 1 mcg/kg and ghrelin 3 mcg/kg (p ¼ .23).
Other Secondary Outcomes
Urge to Drink Juice and Food Craving. Ghrelin dose was not
statistically related to increased urge to drink juice (F2,40 ¼ 1.16,
p ¼ .32; Figure 1B) or to food cravings questionnaire scores (F2,39
¼ .28, p ¼ .76). Table S1 in Supplement 1 shows the mean and
standard deviation for alcohol and juice urge increases in the
three groups collapsed across the two alcohol trials and collapsed
across the two juice trials.
Although the study was not powered to examine a dose by
cue type interaction, this was also explored via a 3 (dose)  2
(cue)  2 (trial) ANCOVA, with standard drink units the day before
and baseline ghrelin as covariates and change in urge as the
dependent variable. However, relative to Rohsenow et al. (26),
which had an average cell size of 26 and only two doses
conditions, these exploratory analyses were compromised by a
lack of statistical power with a cell size of 15 (relative to a main
effect, the power to detect an interaction is based on half the cell
size). In this analysis, a cue effect was demonstrated (F1,45 ¼ 4.08,
p ¼ .049) and there was a trend for a dose effect (F2,45 ¼ 3.05, p ¼
.057), but the cue by dose interaction was not significant (F2,45 ¼
1.12, p ¼ .33).
We also examined correlations between increases in urge for
juice, food, and alcohol in trials 1 and 2 and then again in trials
3 and 4. For the whole sample, alcohol and juice urge increases
were related in first and second trials (r43 ¼ .45, p ¼ .002) and
third and fourth trials (r43 ¼ .48, p ¼ .001). However, the
Table 2. Demographics and Baseline Characteristics of the Enrolled Sample
Total Sample Placebo Ghrelin 1 mcg/Kg Ghrelin 3 mcg/Kg p Value
Number (n) 45 18 13 14
Female Subjects (%) 36 39 31 36 .90
Age (Years)
Range 25–62 28–62 25–57 25–58
Mean  SD 44.7  9.1 46.6  9.0 42.8  9.8 43.9  8.6
Median 47 48 43 45 .49
Race/Ethnicity (%)
Black 31.1 22.2 38.5 35.7
White 53.3 61.1 46.2 50.0
Latino 4.4 5.6 7.7 0 .88
Others 11.1 11.1 7.7 14.3
BMI (Mean  SD) 25.8  3.1 26.4  2.5 25.2  3.3 25.7  3.7 .56
Age of Onset for Alcohol Problems
Range 12–52 12–52 14–33 15–36
Mean  SD 21.8  8.1 22.9  10.9 20.3  5.2 21.8  6.0
Median 20 20 19 20 .68
90-Day Baseline Drinks/Drinking Day 11.8  6.8 11.8  7.9 11.8  6.8 11.8  5.7 1.00
Number of Drinks the Day Before the Experimental Session 4.5  5.5 4.2  5.3 4.9  5.7 4.5  5.8 .94
Alcohol Dependence Severity (ADS) 11.4  7.0 12.6  8.4 9.0  4.4 12.0  6.8 .35
CIWA-Ar 1.2  1.6 1.7  2.0 1.1  1.4 .6  .8 .15
90-Day Baseline Cigarettes/Daya 14.8  10.5 16.6  10.8 16.4  14.1 11.1  5.1 .42
BMI, body mass index; drink, standard drinking unit; CIWA-Ar, Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised.
a76% of the sample were smokers.
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correlations with an increase in food craving were not correlated
with increases in the other urges, perhaps due to methodological
reasons, given the differing format and number of items
(rs ranged from .08 to.14, ps ranged from .38 to .73). Regarding
the correlations between an increased alcohol and juice urge, this
was most pronounced for the first and second trials for the low
ghrelin dose group (r11 ¼ .61, p ¼ .03) and for the third and fourth
trials for the high ghrelin dose (r12 ¼ .83, p  .001).
Ghrelin Safety. As summarized in Table S2 in Supplement 1,
ghrelin dose did not significantly predict adverse events for the
three postinjection assessments (F2,40 ¼ .97, p ¼ .39). Due to the
short half-life of ghrelin, we also ran a parallel analysis on only the
first two postinjection assessments, and no significant group
differences were found (F2,40 ¼ 1.37, p ¼ .27). There was a
significant dose-dependent effect of ghrelin in reducing MAP for
both the first (F2,34 ¼ 8.39, p ¼ .001) and the second (F2,36 ¼ 9.04,
p ¼ .001) alcohol trials, as well as for both the first (F2,35 ¼ 6.17,
p ¼ .005) and the second (F2,32 ¼ 12.13, p  .001) juice trials
(Table S3 in Supplement 1).
Alcohol and Juice Attention Scales. Ghrelin dose did not
predict the Alcohol Attention Scale (F2,39 ¼ 1.01, p ¼ .38) or the
Juice Attention Scale (F2,39 ¼ .50, p ¼ .61).
Heart Rate. Heart rate was analyzed in the same manner as
MAP. No significant differences were found across drug condi-
tions in HR in all cue-reactivity trials, i.e., first alcohol trial (F2,34 ¼
.72, p ¼ .49), second alcohol trial (F2,36 ¼ 2.71, p ¼ .08), first juice
trial (F2,35 ¼ 1.57, p ¼ .22), and second juice trial (F2,32 ¼ 3.20, p ¼
.054) (Table S3 in Supplement 1).
Salivation. Ghrelin dose-dependently reduced saliva mass
during both the alcohol trials (F2,39 ¼ 5.48, p ¼ .008) and the
juice trials (F2,39 ¼ 8.31, p ¼ .001) (Table S4 in Supplement 1).
Effects of Intravenous Ghrelin Administration to Serum
Ghrelin Levels. As expected, there was a pronounced main effect
for dose administered (F2,39 ¼ 88.0, p  .001), as well as a dose by
time interaction (F2,39 ¼ 82.1, p  .001) (Figure 2). Pairwise
comparisons revealed that all three conditions were statistically
significantly different (all three ps  .001; ghrelin 3 mcg/kg: 934.5
[174.5]; ghrelin 1 mcg/kg: 618.7 [172.7]; and placebo: 122.5
[173.0]).
Correlations between Serum Ghrelin Levels and Urges to
Drink Alcohol or Juice. Serum total ghrelin level was correlated
with the increase in alcohol urge during both the first alcohol trial
(r42 ¼ .40, p ¼ .008, n ¼ 44; Figure 3A) and the second alcohol
trial (r42 ¼ .42, p ¼ .005, n ¼ 44; Figure 3B). Similarly, the
maximum serum ghrelin peak level across the six measurements
correlated with the increase in alcohol urge during both the first
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Figure 1. (A) Increase in alcohol urge by dose, expressed as its increase
compared with the baseline (predrug) value of the Alcohol-Visual
Analogue Scale (dA-VAS). Repeated measures analysis of covariance
indicated that ghrelin dose was statistically related to alcohol urge
increase (F2,40 ¼ 3.36, p ¼ .045), and Bonferroni-corrected pairwise
comparisons revealed that alcohol urge was significantly greater for
ghrelin 3 mcg/kg than placebo (p ¼ .046). The effect size for the increase
in alcohol urge for ghrelin 3 mcg/kg versus placebo was large (d ¼ .94).
(B) Increase in juice urge by dose, expressed as its increase compared with
the baseline (predrug) value of the Juice-Visual Analogue Scale (dJ-VAS).
Repeated measures analysis of covariance indicated that ghrelin dose was
not statistically related to juice urge increase (F2,40 ¼ 1.16, p ¼ .32).
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Figure 2. Total serum ghrelin levels in the three study
groups measured at baseline (15 min) and then after
the first juice trial (6 min), first alcohol trial (17 min),
second juice trial (23 min), second alcohol trial (29
min), and after the experiment (48 min). There was a
pronounced main effect for dose administered (F2,39 ¼
88.0, p  .001), as well as a dose by time interaction
(F2,39 ¼ 82.1, p  .001). Bonferroni-corrected pairwise
comparisons also revealed that all three conditions were
statistically significantly different (all three ps  .001). I.
V., intravenous.
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alcohol trial (r42 ¼ .35, p ¼ .02, n ¼ 44; Figure 3C) and second
alcohol trial (r42 ¼ .31, p ¼ .04, n ¼ 44; Figure 3D). (Likewise, when
only the active cells were considered, these correlations were
r24 ¼ .49, p ¼ .01; r24 ¼ .47, p ¼ .02; r24 ¼ .44, p ¼ .03; and
r24 ¼ .29, p ¼ .16, respectively.) By contrast, neither urge to drink
juice craving nor food craving questionnaires were significantly
correlated with serum ghrelin levels.
Correlations between Serum Ghrelin Levels and MAP, HR,
and Saliva Mass. Serum ghrelin levels were significantly and
inversely correlated with MAP and saliva weight during all trials,
while correlations between serum ghrelin levels and HR were not
statistically significant.
Discussion
This is the first study in which the effects of exogenous
intravenous ghrelin administration on alcohol craving were
studied directly in alcohol-dependent individuals. This study
provides preliminary evidence that ghrelin administration signifi-
cantly increases alcohol craving. This was observed using a well-
validated procedure in a well-controlled setting.
Elevated craving levels are associated with increased relapse
rates; therefore, craving has been proposed as a clinically relevant
endophenotype able to predict alcohol use outcomes (3).
Notably, cue-reactivity has demonstrated utility in eliciting urge
to drink in alcoholics (24), and medications (e.g., the Food and
Drug Administration-approved naltrexone) that reduce alcohol
consumption also reduce alcohol craving in cue-reactivity human
studies (37). As such, the present findings have potentially
important clinical implications, as they suggest ghrelin may play
an important role in increased alcohol craving, which, in turn, may
result in alcohol relapse. Manipulations of the ghrelin signaling
may represent a novel pharmacologic approach for treatment.
This is consistent with preclinical experiments where alcohol
intake and measures of alcohol reward and motivation to
consume alcohol were suppressed by GHS-R1a antagonism
(11,38–40).
The results of this study may also have additional implications.
Examining a treatment target that worsens a pharmacologically
induced symptom as a pathway to developing better treatments
for alcoholism is innovative. Consistent with previous studies
investigating different targets (41), this study shows that with
appropriate safeguards a pharmacologically triggered symptom
provoking study can be safely executed. The ability of ghrelin
administration to increase alcohol urge posits this procedure as a
potential novel pharmacologic challenge. As such, the laboratory
model used here might be considered a novel way to test craving
in the laboratory with anticraving treatments, be they pharmaco-
logic or behavioral.
Consistent with previous literature showing a positive corre-
lation between endogenous blood ghrelin and alcohol craving
(13,18,19), this study provides evidence of a positive significant
correlation between cue-induced increase in alcohol craving and
blood ghrelin levels after exogenous ghrelin administration.
Measuring alcohol craving is difficult to operationalize (28), and
this study suggests that ghrelin may represent a novel biomarker
to indirectly quantify alcohol craving. Here, we only measured
total ghrelin serum levels, although it is reasonable that this did
not influence the study conclusions. In fact, a recent intravenous
acetylated ghrelin infusion pharmacokinetics study demonstrated
a relatively constant acetylated/desacetylated ghrelin ratio, with a
linear relationship between ghrelin infused dose and acetylated
ghrelin levels, as well as between ghrelin infused dose and total
serum ghrelin levels (42). Future studies will have to assess the
acetylated/desacetylated ghrelin ratio after intravenous ghrelin
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Figure 3. Serum total ghrelin level was correlated with the increase in alcohol urge measured by the increase in the Alcohol-Visual Analogue Scale
(dA-VAS) during both the (A) first (p ¼ .008) and the (B) second (p ¼ .005) alcohol cue trials. The maximum serum total ghrelin peak level across the six
measurements was correlated with the increase in alcohol urge both in the (C) first (p ¼ .02) and the (D) second (p ¼ .04) alcohol cue trials.
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administration in alcoholic individuals to further shed light on the
potential role of ghrelin as a novel biomarker in alcoholism.
Ghrelin-related effects on appetite are known (5,6). Notably,
postinfusion serum ghrelin levels were significantly and positively
correlated with alcohol urge but not with juice urge or food
craving. Reward processing plays an important role in the neural
circuitry of cue-elicited alcohol craving (43). As such, our study
provides evidence that ghrelin may play a key role facilitating
alcohol-seeking behaviors. These findings support the concept
that ghrelin’s effects extend beyond energy homeostasis and the
hedonic values of substances and involve mechanisms underlying
the search for rewarding substances such as alcohol, at least in
addicted individuals. This is consistent with preclinical experi-
ments suggesting that ghrelin-induced alcohol intake is driven by
reward and independent from the caloric value of alcohol (10).
However, it is important to note that there was not a dose by cue
type interaction, probably due to the small sample enrolled in this
study or alternatively due to a nonspecific effect of ghrelin on
appetitive behaviors. As such, this study does not fully answer the
question if ghrelin effects were specific for alcohol urge. Future
larger studies are needed to address this question.
The highest expression of GHS-R1a is in the brain. In this study,
intravenous (i.e., peripheral) ghrelin administration resulted in an
acute increase in a brain-mediated behavior, i.e., alcohol craving.
In preclinical experiments, intraperitoneal administration of ghre-
lin results in the same brain effects that are observed when
ghrelin is administered centrally (10). Furthermore, there is
evidence not only that ghrelin is produced centrally (44,45) but
also that circulating human ghrelin may pass from blood to brain
by a saturable system (46).
We observed a significant ghrelin effect in decreasing MAP.
Animal studies consistently show central ghrelin effects in
suppressing sympathetic activity and decreasing MAP and HR
(47,48). Furthermore, ghrelin has been shown to increase nitric
oxide bioactivity in blood vessels, thus decreasing peripheral
vascular resistance (49). In normal subjects, intravenous ghrelin
administration causes a significant MAP decrease without
changes in HR (50). Additionally, suppression of the sympathetic
activity is associated with reduced salivation, which is consistent
with reports of dry mouth as a possible ghrelin-induced effect
(51). While the cue-elicited craving is usually associated with
increased MAP, HR, and salivation, on the other hand, these
measures can be independent of each other in alcoholic
individuals (28). Here, intravenous ghrelin versus placebo did
increase cue-elicited craving, and it did so specifically for alcohol.
On the other hand, ghrelin reduced MAP and salivation with no
significant changes in HR; these effects are consistent with
previous literature (47–51) and suggest a nonspecific pharmaco-
logic effect of exogenous ghrelin, which may have washed out or
masked cue-specific effects on MAP, HR, and salivation. These
observations are consistent with the centrally mediated sympa-
thetic effects of ghrelin, thus suggesting that in our subjects,
ghrelin might have been centrally active. On the other hand, one
may argue that given the large amount of GHS-R1s in the vagal
nerve (52), the effects might have been peripheral. Either way, it is
interesting to note that in addition to the significant effects of
intravenous ghrelin versus placebo on MAP and salivation, we
also found a negative significant correlation between postinfusion
serum ghrelin levels and both MAP and saliva during all cue trials,
thus further supporting the direct and nonspecific pharmacologic
effects of ghrelin on these physiological outcomes. Additionally, a
question may be what effects ghrelin had on catecholamine and
acetylcholine systems and whether this may translate into any
cognitive/affective effects. Ghrelin did not result in changes in
adverse events possibly related to the catecholamine and
acetylcholine systems (e.g., restlessness, nervousness or anxiety,
irritability, depression, or mood disturbances). Additionally, these
symptoms were not significantly related to increase in craving (all
ps  .05; data not shown), thus making it unlikely that these
symptoms may drive some of the alcohol craving measures.
Among the intravenous ghrelin studies conducted with other
populations [reviewed in (53)], only a few looked at possible dose-
response effects. Here, the fact that only the highest ghrelin dose
significantly affected alcohol craving is consistent with a study—
upon which we based ours—indicating ghrelin 3 mcg/kg had a
significantly different pharmacokinetic profile than 1 mcg/kg (22).
This study has a number of strengths; in fact, this study 1) was
the first to use a potential pharmacologically triggered symptom
provoking study to directly demonstrate the role of ghrelin in
alcohol craving; 2) was the first to administer exogenous intra-
venous ghrelin to an addicted population; 3) included a well-
validated procedure that was modified ad hoc; and 4) was
conducted in a strict and well-controlled environment, thus
allowing us to measure in real time cue-elicited craving and
control carefully for several possible confounders (e.g., recent
alcohol and food intake). Limitations of the study include the
small sample and the short duration of intravenous ghrelin
administration. Future studies should test the effects of more
prolonged exposure to ghrelin on alcohol craving and larger
samples should be considered. It is also important to keep in
mind that subjective measures of craving are highly variable and
therefore additional paradigms should also be considered. For
example, future studies may investigate the effects of ghrelin on
alcohol self-administration to expand the clinical relevance of this
research. Furthermore, future research should consider genetic
and neuroimaging tools to further investigate the role of ghrelin
in alcoholism.
Consistent with previous studies, cues were presented more
than once to provide a more stable assessment of craving and
were always presented in the same order. The use of a fixed order
was done to allow for the most conservative assessment of
alcohol cue-reactivity (24–26), as previous studies reported a
general lowering of cue-reactivity to any stimulus presented
second (25). Although ghrelin effects were more robust for the
second and the fourth trials (i.e., the alcohol ones), the inclusion
of only one fixed juice-alcohol order still represents a limitation
that should be taken into account in future studies.
Strict inclusionary/exclusionary criteria were applied; therefore,
future studies will need to assess the generalizability of these
results. In particular, obesity was an exclusion to enroll a sample
as homogenous as possible. In fact, ghrelin plays a key role in
regulating the gut-brain axis mechanisms that contribute to
obesity (54); thus, the role of ghrelin might differ in obese versus
nonobese alcoholic individuals. As such, we excluded obese
patients to minimize the risk that differences in ghrelin signaling
among participants might represent a confound to test our
hypothesis. On the other hand, possible future studies might
consider enrolling participants stratified by groups to further
investigate ghrelin specificity to alcohol craving. Finally, the
between-subject (as compared with a crossover) design allowed
us to avoid a possible learning effect on the cue-reactivity and
minimize dropouts. However, while participants were urn
randomized, a crossover design is usually better in terms of
matching study groups.
In conclusion, this study provides the first direct evidence in
humans that intravenous ghrelin administration significantly
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increases alcohol craving in alcohol-dependent heavy-drinking
individuals. As such, this study suggests that ghrelin plays an
important role in the mechanisms of how alcohol-dependent
individuals develop craving for alcohol and that the ghrelin
signalling may represent a novel neuropharmacologic target for
alcohol-dependent patients. Additionally, this study suggests that
intravenous ghrelin administration may represent a novel phar-
macologic challange to trigger alcohol craving in human labo-
ratory studies and that ghrelin may represent a novel biomarker
of alcohol craving in alcoholic individuals. However, given the
small sample and preliminary nature of our findings, future
confirmatory studies are needed.
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